Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
86.44
-7.00 (-7.49%)
NASDAQ · Last Trade: Nov 3rd, 5:52 PM EST
News & Press Releases
Rhythm Pharma (RYTM) Q3 2026 Earnings Call Transcriptfool.com
Japan launch and U.S. demand lifted sales sharply this quarter.
Via The Motley Fool · November 3, 2026
Rhythm Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or acquired HO. The company also outlined plans to advance bivamelagon into Phase
Via MarketBeat · November 3, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 Beats Consensus, but Launch Execution and Spending Weigh on Shareschartmill.com
Via Chartmill · November 3, 2026
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
-- Strong U.S. launch momentum for IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 ---- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter ---- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · November 3, 2026
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · November 2, 2026
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · October 21, 2026
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · October 13, 2026
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · September 22, 2026
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France –
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · September 10, 2026
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Yearsbenzinga.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals has a market
Via Benzinga · September 2, 2026
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Todaybenzinga.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals has a market
Via Benzinga · August 31, 2026
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Revealfool.com
Duquesne Family Office has beefed up its healthcare holdings.
Via The Motley Fool · August 26, 2026
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · August 24, 2026
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Canfool.com
Could this little-known biotech be a hidden gem?
Via The Motley Fool · August 23, 2026
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · August 17, 2026
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalystsmarketbeat.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat.
Smith sai
Via MarketBeat · August 17, 2026
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcriptfool.com
IMCIVREE revenue surged 19% sequentially as HO patient adoption accelerated post-approval.
Via The Motley Fool · August 11, 2026
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or
-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · August 11, 2026
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences.
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · August 4, 2026
Rhythm Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO.
Chief E
Via MarketBeat · August 4, 2026
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Callbenzinga.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call
Via Benzinga · August 4, 2026
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 net product revenue from global sales of IMCIVREE of $71.3 million ---- Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO (n=7) after 16 weeks of treatment --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · August 4, 2026
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) --
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · August 4, 2026
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update.
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · July 21, 2026
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM).
By Rhythm Pharmaceuticals, Inc. · Via GlobeNewswire · July 8, 2026